Technical Analysis for ATRA - Atara Biotherapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bullish Setup | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Earnings Movers | Other | 8.98% | |
| Inside Day | Range Contraction | 8.98% | |
| Pocket Pivot | Bullish Swing Setup | 1.36% | |
| Earnings Movers | Other | 1.36% | |
| Wide Bands | Range Expansion | 1.36% | |
| Up 3 Days in a Row | Strength | 1.36% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 19 hours ago |
| Gap Up Closed | about 22 hours ago |
| Gap Up Partially Closed | about 22 hours ago |
| 10 DMA Support | about 22 hours ago |
| 60 Minute Opening Range Breakout | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/30/2024
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.5 |
| 52 Week Low | 4.965 |
| Average Volume | 138,010 |
| 200-Day Moving Average | 13.04 |
| 50-Day Moving Average | 8.25 |
| 20-Day Moving Average | 8.67 |
| 10-Day Moving Average | 8.98 |
| Average True Range | 0.68 |
| RSI (14) | 61.98 |
| ADX | 30.58 |
| +DI | 30.73 |
| -DI | 12.43 |
| Chandelier Exit (Long, 3 ATRs) | 8.02 |
| Chandelier Exit (Short, 3 ATRs) | 9.23 |
| Upper Bollinger Bands | 9.93 |
| Lower Bollinger Band | 7.42 |
| Percent B (%b) | 0.91 |
| BandWidth | 28.89 |
| MACD Line | 0.31 |
| MACD Signal Line | 0.24 |
| MACD Histogram | 0.0722 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.24 | ||||
| Resistance 3 (R3) | 11.11 | 10.46 | 10.99 | ||
| Resistance 2 (R2) | 10.46 | 10.07 | 10.53 | 10.90 | |
| Resistance 1 (R1) | 10.09 | 9.83 | 10.28 | 10.22 | 10.81 |
| Pivot Point | 9.44 | 9.44 | 9.54 | 9.51 | 9.44 |
| Support 1 (S1) | 9.07 | 9.05 | 9.26 | 9.20 | 8.61 |
| Support 2 (S2) | 8.42 | 8.81 | 8.49 | 8.52 | |
| Support 3 (S3) | 8.05 | 8.42 | 8.44 | ||
| Support 4 (S4) | 8.18 |
